New COVID Variant BA.2 Spreads Across US

A new COVID-19 variant, BA.3.2, is spreading quickly across the United States after circulating without detection since late 2024. Officials and monitoring systems have identified the variant in both patient samples and wastewater, indicating broad community transmission. The strain has been nicknamed “Cicada” and is described as part of the Omicron lineage.

What happened: BA.3.2 was first identified in Africa in November 2024, and by February 2026 it had been detected in 23 countries. The first U.S. case was recorded in June 2025. Since then, it has been found across 29 U.S. states, including through wastewater surveillance that can reveal shifts in circulating strains before clinical testing alone captures them.

What it means: BA.3.2 carries an estimated 70 to 75 genetic changes in its spike protein compared with the currently predominant SARS-CoV-2 strains. Those differences matter because existing COVID-19 vaccines are designed to target strains from the JN.1 lineage, which has been prevalent since January 2024. The scale of spike-protein divergence is cited as a reason vaccine performance could be reduced against BA.3.2, raising the risk of more infections if the variant continues to expand.

At the same time, the available information does not indicate that BA.3.2 leads to more severe disease than earlier variants. The central concern described is the combination of rapid spread and substantial genetic distance from the strains that current public health strategies and vaccine targeting have been built around. The virus’s ongoing mutation—especially in the spike protein—can help it avoid immune recognition more effectively, which can support higher transmission.

Wastewater monitoring is highlighted as a key early-warning tool for detecting changes in circulating variants. However, state participation in wastewater surveillance has declined since 2022, which may make it harder to spot and track emerging strain shifts consistently across the country. That creates uncertainty around how quickly BA.3.2’s footprint can be mapped and how promptly public health responses can be adjusted.

Beyond the United States, the variant’s presence in 23 countries by February 2026 underscores the cross-border nature of variant spread and the importance of coordinated monitoring. The main unknowns remain how much vaccine effectiveness is reduced in practice against BA.3.2 and how surveillance gaps may affect the speed and precision of detection as the variant continues to circulate.